Given this growing and substantial body of evidence, including several meta-analyses supporting the use of SGLT-2 inhibitors in cardiovascular disease, the United States Food and Drug Administration has expanded indications for the use of SGLT2 inhibitors as a first-line therapy and a component of the goal-directed medical treatment of CHF; specifically, SGLT-2 inhibitors have gained a 1A recommendation for use in the treatment of heart failure with reduced ejection fraction [12,13]. This evidence concerns the gene SLC5A2 and cardiovascular disorder.